Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy
June 17, 2026 updated by: Centre Hospitalier Universitaire de Nīmes
Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study
The main objective of this study is to establish an optimal threshold Early parathormon (PTH) assay in order to exclude hypoparathyroidism , that is to say to obtain a negative predictive value of hypoparathyroidism highest possible.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gard
-
Nîmes, Gard, France, 30029
- CHU de Nîmes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Included patients underwent total thyroidectomy from 1 February 2012 to 1 December 2013 at the Nîmes University Hospital
Description
Inclusion Criteria:
- Patients consecutively operated on between February 1, 2012 and December 1, 2013
- Total thyroidectomy +/- lymphadenectomy
- Respect of clinicobiological protocol presented above
- The ( the ) patient ( e) was informed ( e) on the implementation of the study 's objectives, constraints and patient rights
- The ( the ) patient ( e) is under ( e) at least 18 years
Exclusion Criteria:
- The ( the ) patient ( e) is under guardianship, curatorship or under guard saves justice
- It is not possible to give to ( the ) patient ( e) informed information
- History of cervical radiotherapy
- Previous history of dysfunction of the parathyroid glands
- Previous history of surgery of the parathyroid glands
- A history of kidney failure or hepatocellular
- History of osteomalacia or Paget's disease
- unhealed cancer antecedent
- History of sarcoidosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with total thiroidectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the presence/absence of hypoparathyroidism
Time Frame: day 1
|
hypoparathyroidism is defined as: corrected serum calcium Day 1 <1.90 and / or symptoms of hypocalcemia (cramps, tingling of the extremities and peri-oral) to Day 1 authenticated by a VAS score> 3.
|
day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
December 31, 2018
Study Completion (Actual)
December 31, 2018
Study Registration Dates
First Submitted
September 13, 2016
First Submitted That Met QC Criteria
October 4, 2016
First Posted (Estimated)
October 5, 2016
Study Record Updates
Last Update Posted (Actual)
June 18, 2026
Last Update Submitted That Met QC Criteria
June 17, 2026
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2014/BL-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.